Princess Margaret Phase I Consorium (PMP1C)

玛格丽特公主一期联盟 (PMP1C)

• 批准号: 9762723
• 负责人: Steven Grant
• 金额: $ 34.14万
• 依托单位: UNIVERSITY HEALTH NETWORK
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-01 至 2020-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9762723
• 关键词: Address; Adopted; Amendment; American; Antineoplastic Agents; Award; Biological; British Columbia; Canada; Cancer Center; Cause of Death; Clinic; Clinical; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical trial protocol document; Collaborations; Data; Disease; Drug Industry; Drug resistance; Early Therapeutic-Clinical Trials Network; Enrollment; Evaluation; Florida; Fostering; Funding Opportunities; Genotype; Geographic state; Geography; Goals; Healthcare; Industry; Institutes; Investigational Therapies; Laboratories; Lead; Leadership; Malignant Neoplasms; Mentorship; Methodology; Molecular; NCI Center for Cancer Research; National Cancer Institute of Canada Clinical Trials Group; Ontario; Outcome; Pathologist; Patients; Pharmacology; Phase; Positioning Attribute; Prediction of Response to Therapy; Principal Investigator; Process; Province; Research; Research Institute; Research Personnel; Research Support; Resistance; Resources; Safety; Science; Source; Specimen; Technology; Training; Training and Education; Translating; Translational Research; Work; anticancer treatment; base; biomarker development; career development; clinical care; college; design; drug development; drug sensitivity; early phase trial; exome; immune function; innovation; interdisciplinary approach; member; next generation sequencing; novel; novel anticancer drug; quantitative imaging; response; targeted sequencing; tumor; whole genome

The Princess Margaret Phase I Consortium (PMPIC), led by Dr. Lillian Siu, consists of the Princess Margaret Cancer Centre (PM) as its Lead Academic Organization (LAO) and three Affiliated Organizations (AO): Moffitt Cancer Center (MCC), Juravinski Cancer Centre (JCC) and British Columbia Cancer Agency (BCCA). The Specific Aims of PMPIC resonate closely with the goals of the ET-CTN: 1)To conduct innovative, coordinated, efficient, regulatory-compliant and high impact early phase clinical trials in experimental therapeutics, which are designed to address important questions that do not duplicate research supported by the pharmaceutical industry or other sources; 2) To adopt a team science interdisciplinary approach with internal and external collaborations to enhance the optimal evaluation of novel anticancer agents alone or in combination; 3) To accelerate biomarker development and correlative sciences research through comprehensive molecular characterization of tumors obtained from patients enrolled on ET-CTN trials to elucidate mechanism of action, as well as predictors of therapeutic response and/or resistance; and 4) To emphasize training and education to foster career development of junior investigators. PMPIC is committed to actively lead ET-CTN early phase trials as well as to contribute as a meaningful partner to ET-CTN trials led by other Consortia. With a strong Leadership that is supported by the Steering Committee, Translational Research, Clinical Research and Operational Cores, PMPIC embraces a team science approach to conduct the most relevant early phase clinical trials of novel agents alone or in combination. All patients enrolled by the PMPIC will undergo comprehensive molecular characterization using advanced genotyping or targeted sequencing approaches to help identify drivers of drug sensitivity or resistance. This data, along with pharmacological, immune function, and quantitative imaging data, will enable the most optimal biological correlation with clinical outcome. Leveraging resources from other sources including institutional support, the PMP1C will further advances whole exome/whole genome next generation sequencing technologies within the timeframe of this award in the next 5 years.

玛格丽特公主一期联合体（PMPIC）由萧丽莲博士领导，由玛格丽特公主组成 玛格丽特癌症中心 (PM) 作为其领导学术组织 (LAO) 和三个附属组织 (AO)：莫菲特癌症中心 (MCC)、尤拉文斯基癌症中心 (JCC) 和不列颠哥伦比亚省癌症机构 （BCCA）。 PMPIC 的具体目标与 ET-CTN 的目标密切相关： 1) 开展 创新、协调、高效、合规且具有高影响力的早期临床试验 实验疗法，旨在解决不重复研究的重要问题 得到制药业或其他来源的支持； 2）采用跨学科团队科学 内外部合作加强新型抗癌药物的优化评价 单独或组合的药剂； 3）加速生物标志物开发及相关科学研究 通过对 ET-CTN 上登记的患者获得的肿瘤进行全面的分子表征 阐明作用机制以及治疗反应和/或耐药性预测因素的试验；和 4）注重培训教育，促进初级科研人员的职业发展。 PMPIC 致力于积极领导 ET-CTN 早期试验，并为有意义的研究做出贡献 其他联盟领导的 ET-CTN 试验的合作伙伴。凭借强有力的领导力并得到指导委员会的支持 委员会、转化研究、临床研究和运营核心，PMPIC 拥有一个团队 单独或联合使用新药进行最相关的早期临床试验的科学方法 组合。 PMPIC 招募的所有患者都将接受全面的分子表征 使用先进的基因分型或靶向测序方法来帮助识别药物敏感性的驱动因素或 反抗。这些数据与药理学、免疫功能和定量成像数据一起，将 实现与临床结果的最佳生物相关性。利用其他资源 包括机构支持在内的来源，PMP1C下一步将进一步推进全外显子组/全基因组 未来 5 年内，在该奖项的期限内开发新一代测序技术。